Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,101–1,200 of 2,656
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Bilancio, G., Hamzeh, S., Vecchione, N., Russo, D., Iacuzzo, C., Apicella, L., Pietro, R. A. D., Vitale, P., Amicone, M., Pisani, A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061303 · Cited by 4
Aggarwal, R., Bhatt, D. L., Hernandez, A. F., Anker, S. D., Harrington, J., Jones, W. S., Mattheus, M., Petrie, M. C., Steubl, D., Sumin, M., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00657-7 · Cited by 7
Rojas-Rivera, J. E., Caravaca‐Fontán, F., van de Logt, A.-E., Sevillano, Á., Shabaka, A., Ávila, A., Rabasco, C., Cabello, V., Ortíz, A., Quintana, L. F., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf256 · Cited by 6
“…means CR and/or PR; 24h-Prot: proteinuria at 24 h. novel antigens expression [45 , 46 ] and the optimized use of new nephroprotective therapies ( sodium-glucose cotrans-porter 2 inhibitors, mineralocorticoids receptor modulators) , since they may improve the outcomes of proteinuric CKD [47 –49 ].”
Comprehensive management of chronic kidney disease in the old population
Franco, M. E. P., Puente-García, A., Perez-Belmonte, L. M., Pérez, N., Ellingson, S., & Tornero, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2551217 · Cited by 5
Liu, Q., Welsh, P. I., Celis-Morales, C. A., Lees, J. S., Mark, P. B., & Pazzagli, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02936-w · Cited by 5
Horizono, J., Mizumoto, K., Suico, M. A., Kaseda, S., Sannomiya, Y., Tsuhako, H., Owaki, A., Sato, R., Shiraga, M., Kato, R., et al. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.09.008 · Cited by 4
Ramírez-Mulhern, I., Navarro-Sánchez, V., Rivero-Otamendi, E., Sánchez-Mejía, D. E., Zavala-Miranda, M. F., & Mejia-Vilet, J. M. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf548 · Cited by 6
Jin, Y., Sheng, A., Lin, Q., Cen, K., Zhao, M., Feng, C., Fu, H., & Mao, J. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-07023-6 · Cited by 6
Therapy Gaps for Patients with Heart Failure and Reduced Kidney Function: A Prospective Cohort Study
Ma, C.-H., Qi, A. A., Gagnon, L. R., Wang, K., Sadasivan, C., Ghimire, A., Cooper, M. A., Tungsanga, S., Oguaju, B., Vandermeer, B., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70008 · Cited by 5
Yang, C., Joosten, H., Chepulis, L. M., Varallo, F. R., van Dijk, P. R., Crews, D. C., & Vart, P. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100796 · Cited by 8
Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Siddiqi, A. K., Khan, M. S., Kulkarni, A., Hall, M. E., Böhm, M., Díez, J., & Butler, J. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01342-7 · Cited by 5
“…elevated baseline SBP (> 140 mmHg), treatment with 100 mg and 300 mg of cana - gliflozin yielded significant SBP reductions of 12.8 mmHg Empagliflozin (EMPA-KIDNEY) trial, was a randomized, parallel-group, double-blind, placebo-controlled clinical trial that enrolled 6,609 patients with CKD [41].”
InfluentialYu, Y., Shan, Y., Ding, A., & Qian, H. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117605 · Cited by 8
Yamamoto, S., Yuge, H., Okada, H., Saijo, Y., Hasegawa, Y., Nakajima, H., Okamura, T., Nakatani, R., Ushigome, E., Nakanishi, N., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.010 · Cited by 9
Fejes, R., Jámbor, T., Lantos, T., & Tallósy, S. P. (2025) · Medical Sciences · doi:10.3390/medsci14010012 · Cited by 6
Schwartz, A. R., Sosnov, J. A., Brown, J., Delgado, C., Fried, L. F., Tamura, M. K., Morrison, J. W., Navaneethan, S. D., Palevsky, P. M., Rybacki, D. B., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03499 · Cited by 6
A website calculator to benchmark the carbon footprint of haemodialysis
Beige, J., Knöller, S., Pachmann, M., Sommer, F., Barth, H. P., Masanneck, M., Kleophas, W., Schaffron, R., Stracke, S., deGroot, K., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf263 · Cited by 6
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 10
Hushmandi, K., Salarizadeh, N., Einollahi, B., Izadi, M., Doosti, P., Behzadnia, M. J., Cho, W. C., Yousefi, T., Khoshnazar, S. M., Alimohammadi, M., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01824-0 · Cited by 4
“Ongoing trials such as DELIVER and EMPA-KIDNEY are expected to expand understanding of their benefits in broader populations [ 173].”
Non-Proteinuric Diabetic Kidney Disease: A Comprehensive Review
Natarajan, P., Shaik, F., Chatterjee, A., & Prabhakar, S. S. (2026) · Life · doi:10.3390/life16040533 · Cited by 5
Protein Intake and Kidney Outcomes in Nondialysis Chronic Kidney Disease Over 15 Years
Beberashvili, I., Baevsky, T., Shmuel, D., Yoles, I., Rosen, M., & Efrati, S. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.9575 · Cited by 6
Advances in understanding the impact of sex on kidney health and disease
Lees, J. S., Stevens, K. I., Kotwal, S. S., Bruchfeld, A. N., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00654-9 · Cited by 6
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
Agarwal, R., Correa‐Rotter, R., Navaneethan, S. D., Heerspink, H. J. L., Weir, M. R., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Rossing, P. R., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.27036 · Cited by 5
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Management of IgA nephropathy and the expanding role of immunomodulation
Canetta, P. A., & Reich, H. N. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.002 · Cited by 5
“46,47 These trials demonstrated that SGLT2 inhibition can substantially slow the progression of CKD in both diabetic and nondiabetic patients.”
Adverse effects of acute tubular injury on the glomerulus: contributing factors and mechanisms
Bábíčková, J., Yang, H., & Fogo, A. B. (2024) · Pediatric Nephrology · doi:10.1007/s00467-023-06264-7 · Cited by 5
SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
Kim, J. Y., & Kim, S. G. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.1.9 · Cited by 4
Miquel-Rodríguez, R., González-Toledo, B., Pérez-Gómez, M. V., Cobo-Caso, M. Á., Delgado-Mallén, P., Estupiñán, S., Cruz, C., Martin, L. D., González‐Rinne, F., Delgado, A. G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095036 · Cited by 5
Boss, K., Stolpe, S., Müller, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206066 · Cited by 4
Karagiannidis, A. G., Theodorakopoulou, M. P., Alexandrou, M. E., Iatridi, F., Karkamani, E., Anastasiou, V., Mykoniatis, I., Kamperidis, V., Strippoli, G. F., & Sarafidis, P. A. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14335 · Cited by 7
Curovic, V. R., STOUGAARD, E. B., & Hansen, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16007 · Cited by 4
“31 The absolute benefits for kidney and cardiovascular outcomes of SGLT-2i treatment seem to be substantially larger in people with overt albuminuria than without, whereas the relative benefits appear consistent across albuminuria categories.”
Xu, B., Zhang, T., Kang, B., Yang, X., Li, S., Chen, J., He, Z., & Zhou, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07653-2 · Cited by 4
Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry
Tuttle, K. R., Kornowske, L. M., Jones, C. R., Daratha, K. B., Alicic, R. Z., Reynolds, C., Neumiller, J. J., Bensink, M. E., Gong, W., Norris, K. C., et al. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.100981 · Cited by 5
Another Win for SGLT2 Inhibitors in Chronic Kidney Disease
Leaf, D. E., & Bansal, N. (2025) · New England Journal of Medicine · doi:10.1056/nejme2500233 · Cited by 5
Chronic kidney disease in patients with diabetes mellitus: new challenges
Шамхалова, М. Ш., Sukhareva, O. Y., Martynov, S. A., Severina, A. S., Vikulova, O. K., Trubitsyna, N. P., Николаевна, Н. О., Zaytseva, N. V., Shestakova, M. V., Dedov, I. I., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm13268 · Cited by 6
Wang, L., Tang, Y., Buckley, A. F., & Spurney, R. F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319424 · Cited by 4
Nomenclature of renal involvement in diabetes mellitus: unify to manage diversity
Marqués, M., Portolés, J. M., Fernández, C. M., Ortíz, A., & Navarro‐González, J. F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1533011 · Cited by 7
“…in EMPA-KIDNEY support the notion that eGFR slopes on these drugs may be close to zero, i.e., slower than the age-associated slopes, supporting the notion that age-associated GFR loss may be responsive to therapeutic intervention, at least for the duration of current clinical trials (38, 52–54).”
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
Hobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Jones, L., Hirst, J. A., Mort, S., & Yu, L. (2025) · Health Technology Assessment · doi:10.3310/pyft6977 · Cited by 4
Oda, Y., Nishi, H., Sekiguchi, M., Odawara, M., & Nangaku, M. (2025) · Kidney Diseases · doi:10.1159/000545626 · Cited by 4
Nishida, J., Yamakawa, M., Miura, S., & Yasutomi, M. (2025) · CEN Case Reports · doi:10.1007/s13730-025-00990-7 · Cited by 5
Safety of Drugs in Breastfeeding Women With CKD
Parnizari, P., Hladunewich, M., & Zipursky, J. S. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.038 · Cited by 4
Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
Ueda, H., Tsuboi, N., Matsumoto, K., Fukunaga, S., Shimizu, A., Okabe, M., Yokote, S., Sasaki, T., & Yokoo, T. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.042 · Cited by 6
Santamaría, R., Escobar, C., Aranda, U., Palacios, B., Capel, M., Hernández, I., Cebrián, A., Alcázar, R., & Gorostidi, M. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501340 · Cited by 5
The Role of miR-802 in Diabetic Kidney Disease: Diagnostic and Therapeutic Insights
Tejera‐Muñoz, A., Marchant, V. A., Tejedor-Santamaria, L., Opazo-Ríos, L., Lavoz, C., Gimeno, M. J., Aceña, J. L., Ruiz‐Ortega, M., & Rodrigues-Díez, R. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125474 · Cited by 5
Song, Y., Yan, F., Yu, Y., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2525393 · Cited by 4
“Trials such as DAPA–CKD and EMPA–Kidney have demonstrated that by lowering the elevated UACR, SGLT2 inhibitors protect CKD patients from worsening renal function and decompensated heart failure, regardless of their diabetes status [20,21].”
Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure
Bonifant, G. C., Davis, S. N., & Weir, M. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf083 · Cited by 6
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040382 · Cited by 5
“With respect to CKM risk factors, 63.5% of the patients had a history of hypertension, 50.6% had hypertriglyceridemia, 67.8% had T2D, 74.0% had metabolic syndrome, and 67.3% had CKD.”
InfluentialEmpagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis
Doi, Y., Shinzawa, M., Arisato, T., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.049 · Cited by 4
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
“73 m(2), or an eGFR more than 45 but less than 90 mL/ min/1,73 m(2) and an ACR ≥ 200 mg/g [50].”
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two new meta-analyses
Mayne, K. J., Preiss, D., & Herrington, W. G. (2023) · British Journal of Cardiology · doi:10.5837/bjc.2023.003 · Cited by 4
Kaku, K., Nakayama, Y., Yabuuchi, J., Naito, Y., & Kanasaki, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2213477 · Cited by 4
Chanawong, A., Uitrakul, S., Incomenoy, S., & Poonchuay, N. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/5581417 · Cited by 8
Singh, A. K., Singh, A. K., Singh, A., et al. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102789 · Cited by 4
Milder, T. Y., Greenfield, J. R., & Milder, D. A. (2023) · Anaesthesia · doi:10.1111/anae.16068 · Cited by 4
“Amongst the heart failure and renal SGLT2i outcome studies, there was one case of ketoacidosis in a patient without diabetes randomised to empagliflozin treatment in the EMPA-KIDNEY study [2].”
Truscello, L., Nobre, D., Sabaratnam, V., Bonny, O., Wuerzner, G., Burnier, M., Fakhouri, F., Pruijm, M. T., & Zanchi, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1230227 · Cited by 9
“Landmark randomized controlled trials (RCT) with empagliflozin (5), canagliflozin (6), dapagliflozin (7) and finerenone (8) improved cardio-renal outcomes when prescribed to patients with proteinuric DKD.”
BackgroundDiagnostik und Therapie IgA Nephropathie – 2023
Schimpf, J., Kronbichler, A., Windpessl, M., Zitt, E., Eller, K., Säemann, M. D., Lhotta, K., & Rudnicki, M. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02257-6 · Cited by 7
Refractory IgA Nephropathy: A Challenge for Future Nephrologists
Leo, V. D., Annese, F., Papadia, F., Russo, M. S., Giliberti, M., Sallustio, F., & Gesualdo, L. (2024) · Medicina · doi:10.3390/medicina60020274 · Cited by 5
Carvalho, M., & Heilberg, I. P. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0146en · Cited by 4
“In 2019 and 2021, DAPA-CKD and CREDENCE (which only involved diabetics) and, in 2022, the EMPA-KIDNEY demonstrated that iSGLT2 improves renal outcomes and delays the progression of CKD, regardless of the patient having DM and in all KDIGO 7,8 risk categories.”
BackgroundHuang, C., & Lee, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051387 · Cited by 4
Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials
Hamid, A., Greene, S. J., Mehta, A. N., Butler, J., & Khan, M. S. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00668-8 · Cited by 3
“Total eGFR slope in the placebo arm of the EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-Kidney trials were -2.28, -2.62, and -2.92 ml/min/1.73m 2 , respectively [4, 15 •• , 16].”
InfluentialEspinoza, I. M., Choos, E. N. D., ECELBARGER, C. A., & Shepard, B. D. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00029.2024 · Cited by 5
Basutkar, R. S., Cutinha, R. M., Sathish, V., Shahil, A., & Najad Saneen, C. K. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998301228240625065230 · Cited by 4
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study
Sinha, B., & Ghosal, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01635-1 · Cited by 4
Correa-Rotter, R., Wheeler, D. C., & McEwan, P. C. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02950-6 · Cited by 4
Ikeme, J. C., Madden, E., Lamprea-Montealegre, J. A., Chu, C. D., Shlipak, M. G., McCoy, I. E., & Estrella, M. M. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000536 · Cited by 5
Yan, H., Wang, W. J., Li, Y., Qi, Y., Lu, R., Zhou, Y., Zhang, W., Liu, S., Pang, H., Fang, Y., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-087617 · Cited by 6
“20 21 However, due to a lack of safety and efficacy data, SGLT2 inhibitors are not validated in those with an eGFR below 20 mL/min/1.73 m 2 , and dialysis is generally listed as a contraindication to administration.”
BackgroundInfluentialXu, B., Kang, B., Tang, F., Zhou, J., & He, Z. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2399073 · Cited by 4
Radić, J., Vučković, M., Đogaš, H., Grubić, M., Belančić, A., Tandara, L., Šegvić, L. Š., Novak, I., & Radić, M. (2024) · Medicina · doi:10.3390/medicina60101643 · Cited by 4
Seidita, A., Mandreucci, F., Pistone, M., Calderone, S., Giuliano, A., Chiavetta, M., Giannitrapani, L., Citarrella, R., Soresi, M., Licata, A., et al. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1829 · Cited by 4
Emerging perspectives in the management of IgA nephropathy: a comprehensive review
Gomes, A. M., Schau, B., & Farinha, A. (2024) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000264 · Cited by 6
“74 The endothelin pathway, as previously mentioned, has also emerged as a promising therapeutic target and the focus of new research in the area.”
Ten tips in lupus nephritis management
Teoh, S. T. Y., Yap, D. Y. H., & Chan, T. M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae376 · Cited by 4
Lee, Y. J., Kim, J., Yu, D. H., Je, N. K., & Rhee, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-83321-7 · Cited by 9
Ghukasyan, H., Navalha, D. D. P., Romero, I. P., Wolwacz, M. V. P., Ghahramanyan, A., Ngan, C. W. T., de Melo, M. H. S. T., Dagostin, C. S., & Quirós, L. G.-L. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.12.005 · Cited by 7
Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
Bae, J. H., Choi, J., Kim, N. H., & Kim, S. G. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.015 · Cited by 5
Hansrivijit, P., Tesfaye, H., Wexler, D. J., Abdi, R., Patorno, E., & Paik, J. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020651 · Cited by 5
“Although KTRs with treated T2D were excluded from RCTs of SGLT2i [6–8], the rise in SGLT2i utilization in recent years suggests that clinicians are nonetheless prescribing these medications to KTRs with T2D.”
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
Portalatin, G. M., Hong‐McAtee, I., Burgner, A. M., Gould, E. R., & Hunley, T. E. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1521425 · Cited by 7
Górriz, J. L., Gil, F. A., López, M. A. B., Soto, A. B., Cabrera, F. J. C., Cisneros, A., Guerrero, S. C., Conejos, M. D., Cabello, I. E., Planelles, M., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.02.001 · Cited by 4
Gorga, S. M., Beck, T., Chaudhry, P. M., DeFreitas, M. J., Fuhrman, D. Y., Joseph, C., Krawczeski, C. D., Kwiatkowski, D. M., Starr, M. C., Harer, M. W., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040630 · Cited by 5
“92 A recent single-center retrospective study evaluated dapagli-flozin’s safety profile and effectiveness (sodium–glucose cotransporter inhibition) in children with CKD. 93 The investigators reported that over a 15-month period, there was stabilization of eGFR and a reduction in albuminuria and…”
Tsur, A., Cahn, A., Hanoch, L., & Pollack, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16329 · Cited by 6
Rivas‐Otero, D., González‐Vidal, T., Agüeria‐Cabal, P., Ramos‐Ruiz, G., Jiménez‐Fonseca, P., Lambert, C., Pujante, P., Torre, E. L. M., García‐Villarino, M., & Delgado, E. (2025) · Cancer Medicine · doi:10.1002/cam4.70807 · Cited by 4
“While SGLT2i were originally developed to treat diabetes, they have also been proven effective in the treatment of heart failure [3–7] and chronic kidney disease [8–10].”
Chackochan, A., Rashid, M., Reghunath, S. R., Poojari, P. G., Thunga, G., Nagri, S. K., Guddattu, V., Shenoy, R. P., Shenoy, V. P., & Acharya, L. D. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251319476 · Cited by 11
McGarvey, C., Doyle, K., Roche, A. D., Mockler, D., Knight, S. P., Kenny, R. A., & Sexton, D. J. (2025) · QJM · doi:10.1093/qjmed/hcaf111 · Cited by 5
Fatima, E., Irfan, H., Fatima, F., Jain, J., Rehman, O. U., Sehar, A., Ahmad, B., Kumari, S., & Akilimali, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003357 · Cited by 6
Liu, J.-J., Liu, S., Gurung, R. L., Lee, J., Zheng, H., Ang, K., Chan, C., Lee, L. S., Han, S. H. Y., Kovalik, J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf281 · Cited by 6
Olsen, E., Søraas, C. L., Schmieder, R. E., Jamerson, K., MacDonald, T. M., Mancia, G., Heimark, S., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf093 · Cited by 6
MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF
Mendonça, L., Neves, J. S., Testani, J., Zannad, F. M., & Ferreira, J. P. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102514 · Cited by 6
Li, J., Qiao, J., Zhang, S., Zhong, J., Chen, K., Lin, Y. C., Li, Y., Jin, Y., Yao, Y., Zhai, A., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02749-3 · Cited by 8
“Some studies have shown that SGLT-2is is effective not only for DM, but also shows good therapeutic effects in various diseases, such as hyperuricemia, cardiovascular disease, kidney damage, and chronic kidney disease [17, 18].”
Jenssen, T. G., Bodegård, J., Sveen, K. A., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04171-7 · Cited by 4
“In addition to its antihyperglycemic effect, treatment with a SGLT-2 inhibitor and/or RAS inhibitor provides many benefits to patients with CKD, including reduced albuminuria and proteinuria, delayed CKD progression, and prevention of renal and cardiovascular events and death [1, 8].”
Vargas-Brochero, M. J., Russo, I., Mazzierli, T., Cara, A., Berti, G. M., Milheiro, J., Thongprayoon, C., Allinovi, M., Somma, C., Raglianti, V., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf197 · Cited by 16
“…the initiation of the RAAS blocker and introduction of the SGLT2i is not precise (at least 4 weeks before screening in the DAPA-CKD trial and 8– 12 weeks in the EMPA-KIDNEY trial), making it difficult to tease out the independent antiproteinuric effect of the SGLT2i from the RAAS blocker [3 , 20 ].”
Ortíz, A., Quiroga, B., Dı́ez, J., Martín, F. J. E. S., Ramirez, L., Maraver, M. P., Asensio, M. L. M.-B., Arija, J. Á. A., Fernández, J. L. A.-O., Córdoba, R., et al. (2023) · Nefrología · doi:10.1016/j.nefro.2023.02.004 · Cited by 4
Albuminuria and cardiorenal risk
Georgianos, P. I., Dounousi, E. C., & Liakopoulos, V. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001055 · Cited by 5
Li, Q., Nishi, H., Inoue, R., Ueda, S., & Nangaku, M. (2023) · Nephrology · doi:10.1111/nep.14164 · Cited by 4
A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
Cunningham, C., Jabri, A., Alhuneafat, L., & Aneja, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101817 · Cited by 7
Has the time come to step up to “triple therapy” for the treatment of diabetic kidney disease?
Patoulias, D., Popovic, D. S., Fragakis, N., & Rizzo, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110726 · Cited by 4
Chiu, N., Aggarwal, R., Chiu, L., Vaduganathan, M., Fonarow, G. C., & Bhatt, D. L. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100349 · Cited by 4
Dwyer, J. P., Agiro, A., Desai, P., & Cremisi, H. D. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2237679 · Cited by 5
Zhou, Y., Wang, F., Wen, F.-F., Li, C., & Ye, T.-T. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2250949 · Cited by 4
“However, the CREDENCE Clinical Trials, EMPA-KIDNEY Clinical Trials, and SCORED Clinical Trials concluded that there were no significant difference in the risk of lower extremity amputation between the SGLT2i and placebo groups [2,21,42].”
BackgroundCombination therapy with kidney protective therapies: optimizing the benefits?
Kotwal, S. S., Perkovic, E., & Perkovic, V. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000929 · Cited by 4
Dewulf, J. P., Chevalier, N., Marie, S., et al. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107712 · Cited by 4
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.